BWAY BrainsWay Ltd.
USHealthcareAs of 2026-08-24
Why BWAY matters now
BrainsWay Ltd. (BWAY) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.19 with -3.73% on the session and $556.6M in market capitalization; recent performance reads 1-month +0.00% and YTD +56.57%.
The latest financial table shown here is Q1 2026, with revenue of $15.5M, net income of $2.3M, and EPS of $0.12. Investors can compare that operating picture with valuation signals such as P/E 71.36 and FCF yield 1.9%.
The latest indexable market news headline is "Brainsway (BWAY) Upgraded to Buy: Here's Why" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $16.00; recent insider activity includes Mitrany Rayten Michal Ety filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
71.36
PEG
0.44
P/B
7.33
P/S
9.64
EV/EBITDA
72.91
DCF Value
$-14.82
FCF Yield
1.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.5%
Operating Margin
10.1%
Net Margin
14.6%
ROE
12.3%
ROA
7.5%
ROIC
6.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.5M | $2.3M | $0.12 |
| Q4 2025 | $14.5M | $2.9M | $0.14 |
| FY 2025 | $52.2M | $7.6M | $0.36 |
| Q3 2025 | $13.5M | $1.6M | $0.04 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$16.00
Target (Median)
$16.00
Target Range
$15.00 - $17.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
IL
Exchange
—
Beta
0.15
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.